This study analyzed FDA Adverse Event Reporting System data for Sublocade and Brixadi for the 12 months following their U.S. commercial launches. Adverse events were infrequent for both medications, supporting a favorable safety profile for long-acting injectable buprenorphine in the real-world treatment of moderate to severe opioid use disorder.